Overview

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(SacubitrilValsartan)
Phase:
PHASE3
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
sacubitril
Valsartan